News · 26 weeks44+180%
2026-03-012026-08-23
Mix2890d
- Insider15(54%)
- SEC Filings7(25%)
- Earnings3(11%)
- Leadership1(4%)
- Analyst1(4%)
- Other1(4%)
Latest news
25 items- SECSEC Form 144 filed by SI-BONE Inc.144 - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERChief Executive Officer Francis Laura sold $1,088,201 worth of shares (55,807 units at $19.50) as part of a pre-agreed trading plan (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Op & Financial Officer Maheshwari Anshul sold $337,138 worth of shares (16,975 units at $19.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 234,920 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form 144 filed by SI-BONE Inc.144 - SI-BONE, Inc. (0001459839) (Subject)
- SECSEC Form 144 filed by SI-BONE Inc.144 - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERChief Executive Officer Francis Laura sold $279,065 worth of shares (14,956 units at $18.66), decreasing direct ownership by 2% to 493,900 units (SEC Form 4) (tax liability)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERSVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $69,411 worth of shares (3,725 units at $18.63), decreasing direct ownership by 1% to 273,650 units (SEC Form 4) (tax liability)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Financial Officer Maheshwari Anshul sold $87,016 worth of shares (4,665 units at $18.65), decreasing direct ownership by 2% to 251,895 units (SEC Form 4) to cover withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form SCHEDULE 13G filed by SI-BONE Inc.SCHEDULE 13G - SI-BONE, Inc. (0001459839) (Subject)
- INSIDERDirector Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $369,214 worth of shares (20,000 units at $18.46) as part of a pre-agreed trading plan (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- SECSEC Form 10-Q filed by SI-BONE Inc.10-Q - SI-BONE, Inc. (0001459839) (Filer)
- SECSEC Form 144 filed by SI-BONE Inc.144 - SI-BONE, Inc. (0001459839) (Subject)
- SECSI-BONE Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SI-BONE, Inc. (0001459839) (Filer)
- PRSI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 GuidanceDelivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $56.0 million, representing growth of 15.2%U.S. revenue of $53.2 million, representing growth of 14.7%Gross margin of 79.5%Net loss of $4.1 million, representing an improvement of 33.6%Positive adjusted EBITDA of $2.8 million, an improvement of 178.0%Positive cash from operations of $0.8 million$145.9 million in cash and equivalents, representing a sequential increase of $1.3 million Recent Operational Highlights (any comparisons are to the prior year period) 1,715
- ANALYSTUBS initiated coverage on SI-BONE with a new price targetUBS initiated coverage of SI-BONE with a rating of Buy and set a new price target of $24.00
- PRSI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the second quarter of 2026 after market close on Monday, August 3, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/4chyjb8g/. Live audio of the webcast will be available on the "Investors" section of the company’s website at: www.si-bone.com. The webca
- PRViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its BoardIan Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets disciplineTom West, who led Intersect ENT to its $1.1 billion acquisition by Medtronic and Nalu Medical to its $600 million acquisition by Boston Scientific, joins as an Independent Board MemberAppointments build the financial and governance foundation for ViCentra’s next phase, following the recent scale-up of commercial manufacturing UTRECHT, The Netherlands, July 14, 2026 (GLOBE NEWSWIRE) -- ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced the appointment of Ian Wells as Ch
- INSIDERSVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $52,375 worth of shares (3,134 units at $16.71), decreasing direct ownership by 1% to 277,375 units (SEC Form 4) (withholding tax)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERChief Financial Officer Maheshwari Anshul sold $55,627 worth of shares (3,317 units at $16.77), decreasing direct ownership by 1% to 256,560 units (SEC Form 4) to cover withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector Hilleman Jeryl L was granted 10,957 shares, increasing direct ownership by 33% to 43,772 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
- INSIDERDirector Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)4 - SI-BONE, Inc. (0001459839) (Issuer)
SIBN FAQ
7 questionsWhat does SI-BONE Inc. do?
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Where does SIBN stock trade?
SI-BONE Inc. (SIBN) is listed on NASDAQ.What sector and industry is SIBN in?
SI-BONE Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did SI-BONE Inc. go public?
SI-BONE Inc. (SIBN) completed its IPO in 2018.What are analysts saying about SIBN?
SI-BONE Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $2400.00 price target on 2026-07-28. Recent price targets range from $1900.00 to $3600.00.What companies are similar to SIBN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SIBN side-by-side with any of them on Quantisnow.How can I track SIBN on Quantisnow?
Quantisnow aggregates SI-BONE Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SIBN to receive live email and push alerts on every new disclosure.